Weiss Multi Strategy Advisers LLC Fibrogen Inc Transaction History

Weiss Multi Strategy Advisers LLC

$0
Q1 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$31.0 - $55.72 $700,941 - $1.26 Million	-22,611 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$37.09 - $48.97 $1.39 Million - $1.83 Million	-37,389 Reduced 62.32%	22,611 $839,000
Q3 2020 Nov 16, 2020	SELL	$40.47 - $45.5 $530,318 - $596,232	-13,104 Reduced 17.93%	60,000 $2.47 Million
Q2 2020 Aug 14, 2020	BUY	$32.57 - $42.83 $106,862 - $140,525	3,281 Added 4.7%	73,104 $2.96 Million
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $62,374 - $123,034	-2,677 Reduced 3.69%	69,823 $2.43 Million
Q4 2019 Feb 14, 2020	BUY	$34.58 - $48.06 $2.51 Million - $3.48 Million	72,500 New	72,500 $3.11 Million
Q3 2019 Nov 14, 2019	SELL	$36.98 - $48.45 $240,369 - $314,925	-6,500 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$35.13 - $55.53 $1 Million - $1.58 Million	-28,500 Reduced 81.43%	6,500 $294,000
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $642,450 - $898,650	15,000 Added 75.0%	35,000 $1.9 Million
Q4 2018 Feb 14, 2019	SELL	$37.97 - $60.16 $2.1 Million - $3.33 Million	-55,405 Reduced 73.48%	20,000 $926,000
Q3 2018 Nov 14, 2018	BUY	$56.3 - $67.25 $22,801 - $27,236	405 Added 0.54%	75,405 $4.58 Million
Q2 2018 Aug 14, 2018	SELL	$44.9 - $64.95 $808,200 - $1.17 Million	-18,000 Reduced 19.35%	75,000 $4.7 Million
Q1 2018 May 15, 2018	SELL	$45.35 - $61.65 $90,700 - $123,300	-2,000 Reduced 2.11%	93,000 $4.3 Million
Q4 2017 Feb 14, 2018	SELL	$41.95 - $60.1 $1.05 Million - $1.5 Million	-25,000 Reduced 20.83%	95,000 $4.5 Million
Q3 2017 Nov 14, 2017	BUY	$33.4 - $53.9 $4.01 Million - $6.47 Million	120,000	120,000 $6.46 Million

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.

Account